<DOC>
	<DOCNO>NCT00469937</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs , lithium , may protect normal cell side effect radiation therapy . Giving lithium together radiation therapy may allow high dose radiation therapy give tumor cell kill . PURPOSE : This phase I trial study side effect best dose lithium give together whole-brain radiation therapy treat patient brain metastasis primary cancer outside brain .</brief_summary>
	<brief_title>Ph I Study Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility concurrent lithium carbonate whole-brain radiotherapy , measure safety compliance , patient primary extracranial malignancy brain metastasis . OUTLINE : This open-label , dose-escalation study lithium carbonate . Patients receive oral lithium carbonate twice daily day 1-7 2-4 time daily day 8-21 . Patients undergo whole-brain radiotherapy daily day 8-12 15-19 . Cohorts 3-6 patient receive escalate dos lithium carbonate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Quality life mental status assess baseline , day 1 , 8 , 15 , 1-month post-treatment , periodically thereafter . After completion study treatment , patient follow 1 month periodically thereafter . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Histopathologically confirm extracranial primary malignancy Multiple ( i.e. , &gt; 3 ) brain metastasis OR &lt; 3 metastasis least 1 metastasis &gt; 4.0 cm diameter Not eligible radiosurgery No requirement immediate wholebrain radiotherapy No metastases midbrain brainstem Zubrod performance status 02 Life expectancy ≥ 8 week Platelet count &gt; 100,000/mm^3 ANC &gt; 1,500/mm^3 Hemoglobin ≥ 10 g/dL BUN &lt; 25 mg/dL Creatinine &lt; 1.5 mg/dL Bilirubin &lt; 1.5 mg/dL ALT ≤ 2 time normal Sodium &gt; 136 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologically stable No seizure disorder seizure due brain metastases No medical illness psychiatric condition would preclude completion study treatment No sensory neuropathy ≥ grade 2 No bipolar disorder No thyroid disease No QTc interval prolongation PRIOR CONCURRENT THERAPY : More 2 week since prior concurrent chemotherapy At least 2 week since prior concurrent NSAIDs , angiotensinconverting enzyme inhibitor ( e.g. , enalapril captopril ) , calcium channel blocker , diuretic , selective cyclooxygenase2 inhibitor , acetazolamide , urea , xanthine , alkalinize agent ( e.g. , sodium bicarbonate ) No prior radiotherapy head neck area No prior radiosurgery No concurrent radiotherapy sit No concurrent anticonvulsant due brain metastases No concurrent psychoactive drug No concurrent thyroid medication No concurrent amifostine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>radiation toxicity</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>cognitive/functional effect</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>adult tumor metastatic brain</keyword>
</DOC>